[The role of thymic peptides in regulating ovarian morphogenesis].
Morphological analysis of the postnatal ovary development in mice treated with diverse T-activine doses during first 48 hours has shown that change of the thymic peptides content during neonatal period (single injection of the drug in doze 1,0-25,0 micrograms/l g body weight) results in negative ovariotropic effect, manifestations of which are doze-depending. In the case of administration of 5,0, 10,0, 25,0 micrograms/l kg of T-activine ovaritropic effect is limited with transitory disturbances of follicle genesis and therefore, with the delay of pubescence with the following (by the 10th month) reproductive function rehabilitation. After administration of T-activine 1 micrograms/l g in doze ovary dysgenesis with the regular reproductive disturbances was observed. Morphological and functional manifestations of the ovarian pathology in the case under discussion were similar with that of genetically non-thymus and neonatally thymus-ectomized animals, which, probably, may be considered to be the proof of the suggestion that thymic peptides dysbalanse on the early ontogenesis stages plays an important role in pathogenesis of the ovarian dysfunction in non-thymus animals.
Butorina
O G
OG
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000375:Aging / Q000187:drug effects; D000818:Animals; D000831:Animals, Newborn; D004305:Dose-Response Relationship, Drug; D005260:Female; D051379:Mice; D008808:Mice, Inbred CBA; D009024:Morphogenesis / Q000187:drug effects; D010053:Ovary / Q000187:drug effects* / Q000254:growth & development; D010455:Peptides / Q000008:administration & dosage / Q000502:physiology*; D012741:Sexual Maturation / Q000187:drug effects; D013949:Thymus Extracts / Q000008:administration & dosage; D013950:Thymus Gland / Q000502:physiology*
D000276:Adjuvants, Immunologic; D010455:Peptides; D013949:Thymus Extracts; C036191:T-activin
Rol' timicheskikh peptidov v reguliatsii ovarial'nogo morfogeneza.